Skip to main
  1. Stocks
  2. Kura Oncology
  3. Forecast
KURA

Kura Oncology (KURA) Stock Forecast & Price Target

Kura Oncology (KURA) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Kura Oncology is supported by a rapidly de-risking menin-inhibitor franchise, where KOMZIFTI generated $9.1MM in 2Q26 revenue, 115 new patient starts, and >250 total prescriptions, suggesting strong early commercialization and majority share in the NPM1-mutant AML launch segment. The company’s lead program also showed unusually strong clinical validation, with KOMET-007 delivering 96% CRc in NPM1-mutant AML, 94% 12-month OS, and durable MRD-negative responses, while a $519MM to $580.8MM cash position helps fund multiple registrational studies. Beyond hematology, darlifarnib is expanding the platform into solid tumors with encouraging early data in ccRCC and KRAS-mutant cancers, giving Kura optionality across two high-value oncology franchises.

Bears say

Kura Oncology is facing a fundamentally fragile outlook because its lead asset, ziftomenib, could prove less efficacious in AML than expected while its safety profile may offer little differentiation, prompting a reduced probability of success to 10%. The investment case is further weakened by the inherent risk of clinical trial failure, plus regulatory uncertainty around FDA and foreign approvals, any of which could delay or derail commercialization and pressure the share price. Even though the company is currently well-funded, it may still need additional equity financing to advance development, while intense competition and dependence on biomarker-driven patent strategies and sales execution add more downside risk.

Kura Oncology (KURA) has been analyzed by 9 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Kura Oncology and is not a guaranteed prediction by Public.com or investment advice.

Kura Oncology (KURA) Analyst Forecast & Price Prediction

Get the latest Kura Oncology (KURA) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Kura Oncology (KURA)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Kura Oncology (KURA) Forecast

Analysts have given Kura Oncology (KURA) a Buy based on their latest research and market trends.

According to 9 analysts, Kura Oncology (KURA) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $27, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $27, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Kura Oncology (KURA)


Kura Oncology (KURA) Analyst Forecast & Price Prediction

Get the latest Kura Oncology (KURA) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Kura Oncology (KURA)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover KURA stock data and trends